Study Condition(s): Type 1 Diabetes
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes (PRONTO-Pump)
Study Alias: ITSI
The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an insulin pump in adults with type 1 diabetes.
The results of this study are not yet available.
Here you can find out a bit more about the requirements for volunteers who took part in this study
-Participants must have been diagnosed with type 1 diabetes and have been using insulin continuously for at least 12 months
-Participants must be using an insulin pump with “rapid-acting insulin” for at least 6 months and the same “rapid acting insulin” for at least the past 30 days
-Participants must have experience using Continuous Glucose Monitoring (CGM) or Flash Glucose Monitoring (FGM) for at least 60 days during the past 12 months
-Participants must have hemoglobin A1c (HbA1c) values ≤8.5%
-Participants must have been using the MiniMed 530G or 630G (US) or the MiniMed 640G (EU) insulin pump for at least the past 30 days
-Participants must not have had more than 1 emergency treatment for very low blood glucose or poor glucose control (very high blood sugar or diabetic ketoacidosis) in the last 6 months
-Participants must not have significant abnormal accumulation of fat, loss of fat tissue, or scars just under the skin in areas of infusion or have a history of an infection at an infusion site within 90 days prior to screening
-Participants must not be taking medication for diabetes by mouth or injection, other than rapid-acting insulin via pump in the 90 days prior to screening. Occasional insulin injections by pen or syringe are allowed, for example, due to pump malfunction or unexplained high blood sugar that did not respond to insulin by pump
-Participants must not have major problems with their heart, kidneys, liver, or have a blood disorder
-Participants must not have a history of certain types of cancer nor may they be in treatment for these cancers